Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000186650 | SCV000171106 | benign | not specified | 2014-01-24 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Eurofins Ntd Llc |
RCV000186650 | SCV000203327 | likely benign | not specified | 2017-06-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000471041 | SCV000556229 | likely benign | Progressive sclerosing poliodystrophy | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000712796 | SCV000843327 | likely benign | not provided | 2018-05-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002316396 | SCV000851230 | likely benign | Inborn genetic diseases | 2016-09-16 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Wong Mito Lab, |
RCV000471041 | SCV000887082 | benign | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.2853C>T (NP_002684.1:p.Tyr951=) [GRCH38: NC_000015.10:g.89320894G>A] variant in POLG gene is interpretated to be a Benign based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BS1:The minor allele frequency of this allele is high for Mitochondrial DNA depletion syndrome 4A (Alpers type). BS2:Observation of the variant in controls is inconsistent with penetrance of Mitochondrial DNA depletion syndrome 4A (Alpers type). BP4:Computational evidence/predictors indicate no impact on the POLG structure, function, or protein-protein interaction. Based on the evidence criteria codes applied, the variant is suggested to be Benign. |
Illumina Laboratory Services, |
RCV001116417 | SCV001274490 | uncertain significance | POLG-Related Spectrum Disorders | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Ce |
RCV000712796 | SCV001334802 | likely benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | POLG: BP4, BP7 |
Genome Diagnostics Laboratory, |
RCV001847751 | SCV002105574 | likely benign | Hereditary spastic paraplegia | 2021-03-05 | criteria provided, single submitter | clinical testing | |
Diagnostic Laboratory, |
RCV000712796 | SCV001741885 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000712796 | SCV001928679 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000712796 | SCV001975694 | likely benign | not provided | no assertion criteria provided | clinical testing |